GLP1R and obesity disorder: GLP-1 RAs have demonstrated cardiovascular benefits in patients with T2D, and the recent SELECT trial marked a significant milestone by showcasing, for the first time, a reduction in the composite outcome of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke with weekly subcutaneous semaglutide in individuals with overweight or obesity and cardiovascular disease, without diabetes [[30], [31], [32], [33]].